BioAtla, Inc. Expected to Earn FY2028 Earnings of ($0.09) Per Share (NASDAQ:BCAB)

BioAtla, Inc. (NASDAQ:BCAB) – Stock analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for shares of BioAtla in a report released on Wednesday, March 27th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($0.09) for the year. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for BioAtla’s current full-year earnings is ($2.33) per share.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of BioAtla in a research report on Thursday.

BioAtla Price Performance

BioAtla stock opened at $3.44 on Friday. The stock has a market capitalization of $164.91 million, a price-to-earnings ratio of -1.33 and a beta of 1.02. BioAtla has a 1-year low of $1.24 and a 1-year high of $4.07. The business has a fifty day moving average price of $2.50 and a 200-day moving average price of $2.09.

Hedge Funds Weigh In On BioAtla

Several institutional investors and hedge funds have recently modified their holdings of BCAB. Swiss National Bank lifted its holdings in shares of BioAtla by 17.8% in the 1st quarter. Swiss National Bank now owns 50,200 shares of the company’s stock valued at $251,000 after buying an additional 7,600 shares during the period. BlackRock Inc. lifted its holdings in shares of BioAtla by 0.5% in the 1st quarter. BlackRock Inc. now owns 1,594,238 shares of the company’s stock valued at $7,970,000 after buying an additional 8,344 shares during the period. Ergoteles LLC purchased a new position in shares of BioAtla in the 1st quarter valued at about $79,000. Prudential Financial Inc. purchased a new position in shares of BioAtla in the 1st quarter valued at about $130,000. Finally, XTX Topco Ltd purchased a new position in shares of BioAtla in the 1st quarter valued at about $91,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.